

GP-1643

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 5 2000
MAY 5 2000
TECH CENTER 1600/2900
TECH CENTER 1600/2900

Applicants: Philip John Burke and Richard John Knox

Serial No.: 09/445,865


Art Unit: 1643

Filed: February 11, 2000

Examiner: Not Yet Assigned

For: THERAPEUTIC SYSTEMS

Assistant Commissioner for Patents
Washington, D.C. 20231



RHC

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including nine (9) pages of Form PTO-1449 and a copy of each document cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 01-2507.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,440,859	04-03-1984	Rutter, et al.	435/172
4,530,901	07-23-1985	Weissmann	435/708
4,582,800	04-15-1986	Crowl	435/70
4,677,063	06-30-1987	Mark, et al.	435/68
4,678,751	07-07-1987	Goeddel	435/243
4,704,362	11-03-1987	Itakura, et al.	435/253
4,710,463	12-01-1987	Murray	435/68
4,757,006	07-12-1988	Toole, Jr., et al.	435/70
4,766,075	08-23-1988	Goeddel, et al.	435/240.2
4,810,648	03-07-1989	Stalker	435/191

U.S.S.N.: 09/445,865
 Filed: December 13, 1999
 INFORMATION DISCLOSURE STATEMENT

Foreign Patent Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
0 251 744 A2	01-07-1988	Delta Biotechnology Ltd.	EP
0 258 067 A2	03-02-1988	Delta Biotechnology Ltd.	EP
0 302 473 A2	02-08-1989	Bristol-Myers Co.	EP
0 415 731 A2	03-06-1991	The Wellcome Foundation Ltd.	EP
WO 88/07378 A1	10-06-1988	Cancer Research Campaign Technology Ltd.	PCT
WO 89/10140 A1	11-02-1989	Cancer Research Campaign Technology Ltd.	PCT
WO 90/01063 A1	02-08-1990	Delta Biotechnology Ltd.	PCT
WO 91/09867 A1	07-11-1991	Imperial Cancer Research Technology Ltd.	PCT
WO 91/11201 A1	08-07-1991	Imperial Cancer Research Technology Ltd.	PCT
WO 93/08288 A1	04-29-1993	Cancer Research Campaign Technology Ltd.	PCT
WO 93/13805 A1	07-22-1993	Bagshawe	PCT
WO 93/13806 A1	07-22-1993	Bagshawe	PCT
WO 95/12678 A1	05-11-1995	Cancer Research Campaign Technology Ltd.	PCT
WO 97/07097 A1	02-27-1997	Auckland Division Cancer Society of New Zealand	PCT
WO 97/20580 A1	06-12-1997	AEPACT, Ltd.	PCT
WO 97/24143 A1	07-10-1997	AEPACT, Ltd.	PCT
WO 97/24143 A1	07-10-1997	AEPACT, Ltd.	PCT
WO 98/22577 A1	05-28-1998	Masucci	PCT
WO 98/24478 A2	06-11-1998	AEPACT, Ltd.	PCT

Publications

ANLEZARK, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from *Escherichia coli*--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT)," *Biochem. Pharmacol.* 1992 44(12):2289-95.

BETTER, et al., "Escherichia coli secretion of an active chimeric antibody fragment," *Science* 240(4855):1041-43 (1988).

BIRD, et al., "Single-chain antigen-binding proteins," *Science* 242(4877):423-26 (1988).

BISCHOFF, et al., "An adenovirus mutant that replicates selectively in p53-deficient human tumor cells," *Science* 274(5286):373-76 (1996).

BOLAND, et al., "The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)," *Biochem. Pharmacol.* 41(6-7):867-75 (1991).

BRADL, et al., "Malignant melanoma in transgenic mice," *Proc. Natl. Acad. Sci. U. S. A.* 88(1):164-68 (1991).

BRAWER, "Prostate specific antigen. A review," *Acta. Oncol.* 30(2):161-68 (1991).

CHEN, et al., "Expression of rat liver NAD(P)H:quinone-acceptor oxidoreductase in *Escherichia coli* and mutagenesis in vitro at Arg-177," *Biochem. J.* 284 (Pt 3):855-60 (1992).

CHEN, et al., "Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse," *J. Biol. Chem.* 272(3):1437-39 (1997).

CLARK, et al., "Role of the Bp35 cell surface polypeptide in human B-cell activation," *Proc. Natl. Acad. Sci. U. S. A.* 82(6):1766-70 (1985).

CONNORS & WISSON, "Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity," *Nature* 210(38):866-67 (1966).

CORVALAN & SMITH, "Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids," *Cancer Immunol. Immunother.* 24(2):127-32 (1987).

CORVALAN, et al., "Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids," *Cancer Immunol. Immunother.* 24(2):133-37 (1987).

CORVALAN, et al., "Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody," *Cancer Immunol. Immunother.* 24(2):138-43 (1987).

COTTEN, et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," *Proc. Natl. Acad. Sci. U. S. A.* 89(13):6094-98 (1992).

COUSSENS, et al., "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neuroncogene," *Science* 230(4730):1132-39 (1985).

CULVER, et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," *Science* 256(5063):1550-52 (1992).

CURIEL, "Adenovirus facilitation of molecular conjugate-mediated gene transfer," *Prog. Med. Virol.* 40:1-18 (1993).

DRABEK, et al., "The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954," *Gene Ther.* 4(2):93-100 (1997).

FRIEDLOS, et al., "Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity," *Biochem. Pharmacol.* 44(9):1739-43 (1992).

FRIEDLOS, et al., "Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2)," *Biochem. Pharmacol.* 44(1):25-31 (1992).

FRIEDLOS & KNOX, "Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system," *Biochem. Pharmacol.* 44(4):631-35 (1992).

GILLILAND, et al., "Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells," *Proc. Natl. Acad. Sci. U. S. A.* 85(20):7719-23 (1988).

GREEN, et al., "Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the *E. coli* nitroreductase gene," *Cancer Gene Ther.* 4(4):229-38 (1997).

HARWOOD, et al., "Comparative tumour localization of antibody fragments and intact IgG in nude mice bearing a CEA-producing human colon tumour xenograft," *Eur. J. Cancer Clin. Oncol.* 21(12):1515-22 (1985).

HELLSTRÖM, et al., "Monoclonal mouse antibodies raised against human lung carcinoma," *Cancer Res.* 46(8):3917-23 (1986).

HURRELL, "Monoclonal Hybridoma Antibodies: Techniques and Applications," (CRC Press.

HUSTON, et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*," *Proc. Natl. Acad. Sci. U. S. A.* 85(16):5879-83 (1988).

JACKSON, et al., "The tyrosinase-related protein-1 gene has a structure and promoter sequence very different from tyrosinase," *Nucleic Acids Res.* 19(14):3799-804 (1991).

JAISWAL, "Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression," *J. Biol. Chem.* 269(20):14502-08 (1994).

JAISWAL, "Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6," *Biochemistry*. 29(7):1899-906 (1990).

KHAN & ROSS, "Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships," *Chem. Biol. Interact.* 1(1):27-47 (1969).

KNOX, et al., "The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)," *Cancer Metastasis Rev.* 12(2):195-212 (1993).

KNOX, et al., "Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)," *Biochem. Pharmacol.* 49(11):1641-47 (1995).

KNOX, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase," *Biochem. Pharmacol.* 44(12):2297-301 (1992).

KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," *Cell Struct. Funct.* 16(6):503-10 (1991).

LAEMMLI, "Cleavage of structural proteins during the assembly of the head of bacteriophage T4," *Nature* 227(259):680-5 (1970).

LEDLEY, "Nonviral gene therapy: the promise of genes as pharmaceutical products," *Hum. Gene Ther.* 6(9):1129-44 (1995).

LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide," *J. Biol. Chem.* 237:2981-87 (1962).

LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," *Biochem. and Biophys. Res. Comm.* 4:208-13 (1961).

LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic hydrocarbons," *Biochem. Pharmacol.* 6:53-54 (1961).

LUNDWALL, "Characterization of the gene for prostate-specific antigen, a human glandular kallikrein," *Biochem. Biophys. Res. Commun.* 161(3):1151-9 (1989).

MARTIN & PAPAHAJOPOULOS, et al., "Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting," *J. Biol. Chem.* 257(1):286-8 (1982).

MAUGER, et al., "Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme," *J. Med. Chem.* 37(21):3452-58 (1994).

MICHAEL, et al., "Addition of a short peptide ligand to the adenovirus fiber protein," *Gene Ther.* 2(9):660-68 (1995).

MILLER & VILE, "Targeted vectors for gene therapy," *FASEB J.* 9(2):190-99 (1995).

MORRISON, et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," *Proc. Natl. Acad. Sci. U. S. A.* 81(21):6851-55 (1984).

NÄSSANDER, et al., "In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice," *Cancer Res.* 52(3):646-53 (1992).

NEUBERGER, et al., "Recombinant antibodies possessing novel effector functions," *Nature* 312(5995):604-08 (1984).

O'SULLIVAN, et al., "Comparison of two methods of preparing enzyme-antibody conjugates: application of these conjugates for enzyme immunoassay," *Anal. Biochem.* 100(1):100-08 (1979).

RIEGMAN, et al., "Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene," *Biochem. Biophys. Res. Commun.* 159(1):95-102 (1989).

SAIKI, et al., "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase," *Science* 239(4839):487-91 (1988).

SAMBROOK, et al., Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor:New York (1989).

SCHREWE, et al., "Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression," *Mol. Cell. Biol.* 10(6):2738-48 (1990).

SHARMA, et al., "Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model," *Br. J. Cancer.* 61(5):659-62 (1990).

SHERWOOD, "Advanced drug delivery reviews: enzyme prodrug therapy," *Adv. Drug Del. Rev.* 22:269-88 (1996).

SKERRA, et al., "Assembly of a functional immunoglobulin Fv fragment in *Escherichia coli*," *Science* 240(4855):1038-41 (1988).

U.S.S.N.: 09/445,865
Filed: December 13, 1999
INFORMATION DISCLOSURE STATEMENT

TROWELL, "The cytocidal action of mitotic poisons on lymphocytes *in vitro*,"
Biochemical Pharmacology 5:53-63 (1960).

WAGNER, et al., "Transferrin-polycation conjugates as carriers for DNA uptake into
cells," *Proc. Natl. Acad. Sci. U. S. A.* 87(9):3410-14 (1990).

WARD, et al., "Binding activities of a repertoire of single immunoglobulin variable
domains secreted from *Escherichia coli*," *Nature* 341(6242):544-46 (1989).

WHISSON & CONNORS, "Cure of mice bearing advanced plasma cell tumours with
aniline mustard," *Nature* 206(985):689-91 (1965).

WINTER & MILSTEIN, "Man-made antibodies," *Nature* 349(6307):293-99 (1991).

WU, et al., "Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a
dihydronicotinamide riboside dependent oxidoreductase," *Arch. Biochem. Biophys.* 347(2):221-
28 (1997).


ZOLA, "Monoclonal Antibodies: A manual of techniques," (CRC Press, 1988).

U.S.S.N.: 09/445,865
Filed: December 13, 1999
INFORMATION DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: April 28, 2000


ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 W. Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8795 (fax)

U.S.S.N.: 09/445,865
Filed: December 13, 1999
INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: April 28, 2000


Julie A. Tennyson